Targeted conditioning of Iomab-B ((131)I-anti-CD45) prior to allogeneic hematopoietic cell transplantation versus conventional care in relapsed or refractory acute myeloid leukemia (AML): Preliminary feasibility and safety results from the prospective, randomized phase 3 SIERRA trial Meeting Abstract
| Authors: | Agura, E.; Gyurkocza, B.; Nath, R.; Litzow, M. R.; Tomlinson, B. K.; Abhyankar, S.; Seropian, S.; Stiff, P. J.; Choe, H. K.; Kebriaei, P.; Foran, J. M.; Chen, G.; Levy, M. Y.; Lazarus, H. M.; Giralt, S.; Berger, M. S.; Reddy, V.; Pagel, J. M. |
| Abstract Title: | Targeted conditioning of Iomab-B ((131)I-anti-CD45) prior to allogeneic hematopoietic cell transplantation versus conventional care in relapsed or refractory acute myeloid leukemia (AML): Preliminary feasibility and safety results from the prospective, randomized phase 3 SIERRA trial |
| Meeting Title: | 60th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 132 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Dec 1-4 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2018-11-28 |
| Language: | English |
| ACCESSION: | WOS:000454837603047 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood-2018-99-111914 |
| Notes: | Meeting Abstract: 1017 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
